Clinical Trial Goal
To find out if belumosudil is safe and works well to treat chronic GVHD
You may be able to join this trial if you:
- Are 18 years old or older
- Have chronic GVHD
- Have not been treated with belumosudil
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Belumosudil is drug that blocks ROCK2 in certain cells.
In this trial, you’ll be randomized to 1 of 2 groups. Once you’re randomized, you and the clinical trial doctors won’t know which group you’re in until after the trial is finished:
In this trial, you’ll be randomized to 1 of 2 groups. Once you’re randomized, you and the clinical trial doctors won’t know which group you’re in until after the trial is finished:
- Group 1 – Belumosudil
- Group 2 – Placebo, a pill with no medicine in it
Randomized means doctors will use a computer to assign you to either group. A computer assigns you by chance, like flipping a coin or drawing a name out of a hat. You, your doctor or the clinical trial doctor won’t have any control over which group you’ll be assigned. This means you won’t be able to choose your group.
You’ll get:
- Belumosudil – A pill that you take by mouth 1 or 2 times each day
- Placebo – Group 2 only - A pill that you take by mouth 1 or 2 times each day
You may continue treatment for up to 1 year. You'll have blood tests to see how well the treatment is working. The clinical trial doctors will check your health for up to 1.5 years.
The Food and Drug Administration (FDA) has approved belumosudil to treat chronic GVHD. Using it to treat newly diagnosed chronic GVHD is new and unproven.
Locations
Moffitt Cancer CenterRECRUITING
Tampa, Florida
Dana-Farber Cancer InstituteRECRUITING
Boston, Massachusetts
Memorial Sloan Kettering Cancer CenterRECRUITING
New York, New York
Fred Hutch/University of Washington Cancer ConsortiumRECRUITING
Seattle, Washington
Gaby Desatnik, 206-667-1356, gdesatni@fredhutch.org
Sponsors
collaborator: Sanofi, lead: Fred Hutchinson Cancer Center
